Diabetes mellitus and pancreatic cancer – cause or result?

Czech version

Authors: Pavel Škrha
Authors‘ workplace: II. interní klinika 3. LF UK a FN Královské Vinohrady, Praha, přednosta prof. MUDr. Michal Anděl, CSc.
Published in: Vnitř Lék 2014; 60(9): 787-790
Category:

Overview

Pancreatic cancer is a malignancy with a poor prognosis. Its increased incidence was observed in diabetic patients in the past. However, there is no evidence, whether diabetes is a risk factor for neoplastic transformation, or if it arises secondarily as a result of the tumor. The key is an early detection of cancer to perform pancreatectomy – the only possible curative therapy yet. This requires early diagnostic markers.

Key words:
diabetes mellitus – pancreatectomy – pancreatic cancer

Sources

1. Ben Q, Xu M, Ning X et al. Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer 2011; 47(13): 1928–1937.

2. Li D, Tang H, Hassan MM et al. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011; 22(2): 189–97.

3. Ben Q, Cai Q, Li Z et al. The relationship between new-onset diabetes mellitus and pancreatic cancer risk: A case-control study. Eur J Cancer 2011; 47(2): 248–254.

4. Chari ST, Leibson CL, Rabe KG et al. Pancreatic Cancer-Associated Diabetes Mellitus: Prevalence and Temporal Association With Diagnosis of Cancer. Gastroenterology 2008; 134(1): 95–101.

5. Mizuno S, Nakai Y, Isayama H et al. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Pancreatology 2013; 13(3): 285–289.

6. Pannala R, Leirness JB, Bamlet WR et al. Prevalence and Clinical Profile of Pancreatic Cancer-Associated Diabetes Mellitus. Gastroenterology 2008; 134(4): 981–987.

7. Permert J, Ihse I, Jorfeldt L et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993; 159(2): 101–107.

8. Jee SH, Ohrr H, Sull JW et al. Fasting serum glucose level and cancer risk in Korean men and women. Jama 2005; 293(2): 194–202.

9. Gapstur SM, Gann PH, Lowe W et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000; 283(19): 2552–2558.

10. Taniguchi CM, Emanuelli B, Kahn CR. Critica l nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol 2006;7(2): 85–96.

11. Asano T, Yao Y, Shin S et al. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res 2005; 65(20): 9164–9168.

12. Tanno S, Tanno S, Mitsuuchi Y et al. AKT Activation Up-Regulates Insulin-like Growth Factor I Receptor Expression and Promotes Invasiveness of Human Pancreatic Cancer Cells. Cancer Res 2001; 61(2): 589–593.

13. Asano T, Yao Y, Zhu J et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23(53): 8571–8580.

14. Pantalone D, Ragionieri I, Nesi G. Improved survival in small pancreatic cancer. Dig Surg 2001; 18(1): 41–46.

15. Fisher WE, McCullough PJ, Ray MB et al. Diabetes enhances growth of pancreatic carcinoma cells. Surgery 1988; 104(2): 431–436.

16. Butler AE, Galasso R, Matveyenko A et al. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 2010; 53(1): 21–26.

17. Basso D et al. β-Cell function in pancreatic adenocarcinoma. Pancreas 1994; 9: 332–335.

18. Agustsson T, D‘souza MA, Nowak G et al. Mechanisms for skeletal muscle insulin resistance in patients with pancreatic ductal adenocarcinoma. Nutrition 2011; 27(7–8): 796–801.

19. Permert J, Adrian TE, Jacobsson Pet al. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? The Am J Surg.1993; 165(1): 61–67.

20. Permert J1, Ihse I, Jorfeldt L et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80(8): 1047–1050.

21. Basso D, Greco E, Fogar P et al. Pancreatic cancer-associated diabetes mellitus: An open field for proteomic applications. Clin Chim Acta 2005; 357(2): 184–189.

22. Fogar P, Basso D, Pasquali C et al. Portal but not peripheral serum levels of interleukin 6 could interfere with glucose metabolism in patients with pancreatic cancer. Clin Chim Acta.1998; 277(2): 181–189.

23. Pannala R, Basu A, Petersen GM et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. The Lancet Oncol 2009; 10(1): 88–95.

24. Noy A, Bilezikian JP. Diabetes and pancreatic cancer: Clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab 1994; 79(5): 1223–1231.

25. Chu D, Kohlmann W, Adler DG. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP 2010; 11(3): 203–212.

26. Poruk KE, Gay DZ, Brown K et al. The clinical utility of CA 19–9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 2013; 13(3): 340–351.

27. Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol 1990; 85(4): 350–355.

28. Kosanam H, Prassas I, Chrystoja CC et al. Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Mol Cell Proteomics 2013; 12(10): 2820–2832.

29. Park HD, Kang ES, Kim JW et al. Serum CA19–9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma. Proteomics 2012; 12(23–24): 3590–3597.

30. Zhang P, Zou M, Wen X et al. Development of serum parameters panels for the early detection of pancreatic cancer. Int J Cancer 2014; 134(11): 2646–2655.

31. Willumsen N, Bager CL, Leeming DJ et al. Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. BMC Cancer 2013; 13:554. Dostupné z DOI: <http://doi: 10.1186/1471–2407–13–554>.

32. Fric P, Zavoral M. Early diagnosis of pancreatic adenocarcinoma: role of stroma, surface proteases, and glucose-homeostatic agents. Pancreas 2012; 41(5): 663–670.

33. Bracci PM1, Zhou M, Young S et al. Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study. Cancer 2012; 118(21): 5384–5394.

34. Chung HW, Lim JB, Jang S et al. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma. Cancer Sci 2012; 103(9): 1714–1721.

35. Ikeda Y, Tanji E, Makino N et al. MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer. Mol Cancer Res 2012; 10(2): 259–269.

36. LaConti JJ, Shivapurkar N, Preet A et al. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One 2011; 6(6): e20687.

37. Morimura R, Komatsu S, Ichikawa D et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 2011; 105(11): 1733–1740.

38. Kawaguchi T, Komatsu S, Ichikawa D et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 2013; 108(2): 361–369.

39. Liu R, Chen X, Du Y et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 2012; 58(3): 610–618.

40. Zhu ZM, Xu YF, Su QJ et al. Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma. Mol Cell Biochem 2014; 388(1–2): 39–49.

41. Liu J et al. Combination of plasma microRNAs with serum CA19–9 for early detection of pancreatic cancer. Int J Cancer 2012; 131(3): 683–691.